These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11644)

  • 1. Biologically active components and properties of Bordetella pertussis.
    Morse SI
    Adv Appl Microbiol; 1976; 20():9-26. PubMed ID: 11644
    [No Abstract]   [Full Text] [Related]  

  • 2. Bordetella pertussis toxins.
    Wardlaw AC; Parton R
    Pharmacol Ther; 1982; 19(1):1-53. PubMed ID: 6304790
    [No Abstract]   [Full Text] [Related]  

  • 3. Antigens in whooping cough vaccine and antibody levels induced by vaccination of children.
    Ashworth LA; Robinson A; Irons LI; Morgan CP; Isaacs D
    Lancet; 1983 Oct; 2(8355):878-81. PubMed ID: 6137697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Toxic factors of Bordetella pertussis, with special reference to leukocytosis-promoting factor, histamine-sensitizing factor and hemagglutinins (author's transl)].
    Sato Y
    Tanpakushitsu Kakusan Koso; 1976 Nov; Suppl():164-83. PubMed ID: 194282
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of biological activities of Bordetella pertussis mutants lacking the ability to produce filamentous hemagglutinin with similar activities of other smooth strains.
    Watanabe M; Munoz JJ
    Microbiol Immunol; 1982; 26(10):965-9. PubMed ID: 6298581
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cell components of Bordetella pertussis and their biological activities].
    Sato Y; Arai H
    Tanpakushitsu Kakusan Koso; 1972; 17(2):139-49. PubMed ID: 4337077
    [No Abstract]   [Full Text] [Related]  

  • 8. Do we need a new vaccine to control the re-emergence of pertussis?
    Mills KH; Ross PJ; Allen AC; Wilk MM
    Trends Microbiol; 2014 Feb; 22(2):49-52. PubMed ID: 24485284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
    Winsnes R; Lønnes T; Møgster B; Berdal BP
    Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis.
    Pittman M
    Rev Infect Dis; 1979; 1(3):401-12. PubMed ID: 233166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against intranasal infection of mice with Bordetella pertussis.
    Robinson A; Ashworth LA; Baskerville A; Irons LI
    Dev Biol Stand; 1985; 61():165-72. PubMed ID: 2872102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological correlates in whooping cough.
    Granström M; Granström G
    Vaccine; 1993; 11(4):445-8. PubMed ID: 8470429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antigen of Bordetella pertussis that induces bactericidal antibody and its relationship to protection of mice.
    Ackers JP; Dolby JM
    J Gen Microbiol; 1972 Apr; 70(2):371-82. PubMed ID: 4338965
    [No Abstract]   [Full Text] [Related]  

  • 14. Further contributions to an improved pertussis vaccine: II. New findings in the development of a pertussis vaccine.
    Robbel L; Hungerer KD; Aktories K
    Behring Inst Mitt; 1984 Nov; (76):110-2. PubMed ID: 6098261
    [No Abstract]   [Full Text] [Related]  

  • 15. [Whooping cough--a toxicosis?].
    Finger H; Wirsing von König CH
    Dtsch Med Wochenschr; 1986 Jun; 111(24):950-4. PubMed ID: 2872045
    [No Abstract]   [Full Text] [Related]  

  • 16. Bordetella pertussis, B. parapertussis, vaccines and cycles of whooping cough.
    Bouchez V; Guiso N
    Pathog Dis; 2015 Oct; 73(7):. PubMed ID: 26242280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice.
    Oda M; Cowell JL; Burstyn DG; Manclark CR
    J Infect Dis; 1984 Dec; 150(6):823-33. PubMed ID: 6094673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
    Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
    Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection.
    Suzuki K; Shinzawa N; Ishigaki K; Nakamura K; Abe H; Fukui-Miyazaki A; Ikuta K; Horiguchi Y
    Microbiol Immunol; 2017 Sep; 61(9):371-379. PubMed ID: 28752940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxonomic distribution of the antigen eliciting bactericidal antibody for Bordetella pertussis.
    Dolby JM; Ackers JP
    J Gen Microbiol; 1975 Apr; 87(2):239-44. PubMed ID: 49392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.